NCT05784974View on ClinicalTrials.gov

Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

May 1, 2025

Study Completion Date

May 1, 2028

Conditions
Lung Cancer
Interventions
DRUG

Cadonilimab

15 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.

All Listed Sponsors
lead

The First Hospital of Jilin University

OTHER

NCT05784974 - Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer | Biotech Hunter | Biotech Hunter